SCHEMBL383765

SCHEMBL383765

Cc1ccc(-c2cc(-c3ccc(O)c(C)c3)nc[n+]2[O-])cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
TLR8 Q9NR97 4/20 0.37
HSD17B1 P14061 5/20 0.36
HSD17B2 P37059 5/20 0.36
CDC7 O00311 1/20 0.35
PIM1 P11309 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CLK1 P49759 1/20 0.35
GSK3B P49841 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CSNK2A3 Q8NEV1 1/20 0.35
ESR2 Q92731 3/20 0.35
ESR1 P03372 2/20 0.34
FYN P06241 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385493 0.92 TLR8 (0.43) TLR8HSD17B1HSD17B2CDC7PIM1
SCHEMBL385779 0.89 TLR8 (0.45) TLR8HSD17B1HSD17B2CDC7PIM1
SCHEMBL386252 0.89 TLR8 (0.36) TLR8HSD17B1HSD17B2CDC7PIM1
SCHEMBL385056 0.87 TLR8 (0.47) TP53TLR8ESR1FYNKDM4E
SCHEMBL386262 0.86 ESR1 (0.36) TLR8HSD17B1HSD17B2CDC7PIM1
SCHEMBL386323 0.82 NPC1 (0.42) TP53TLR8HSD17B1HSD17B2CDC7
SCHEMBL386549 0.82 TLR8 (0.38) TLR8ESR2ESR1FYN
SCHEMBL383387 0.80 TLR8 (0.44) TP53TLR8HSD17B1HSD17B2ESR2
SCHEMBL386324 0.80 PIM1 (0.53) TP53TLR8HSD17B1HSD17B2CDC7
SCHEMBL385491 0.80 TLR8 (0.36) TP53TLR8HSD17B1HSD17B2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 TP53 1272/4885TDP1 2331/4885TLR8 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.